Mizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-term

August 11, 2023
Mizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-termMizuho’s Jared Holz on Novo Nordisk: There’s not much upside near-term

Jared Holz, Mizuho healthcare strategist, joins ‘Squawk Box’ to discuss Novo Nordisk’s quarterly earnings results, which hiked its outlook for 2023 after reporting a 30% increase in sales for the first half of the year, powered by strong demand for its weight loss drugs, and more.

Share This

Latest Mizuho News

Selective opportunities in software stocks amid sell-off, says Mizuho’s Gregg Moskowitz

Selective opportunities in software stocks amid sell-off, says Mizuho’s Gregg Moskowitz

February 17, 2026
Eli Lilly has already won the weight loss drug battle, says Mizuho’s Jared Holz

Eli Lilly has already won the weight loss drug battle, says Mizuho’s Jared Holz

February 23, 2026
Polymarket settling with USDC helped drive our upgrade of Circle, says Mizuho’s Dan Dolev

Polymarket settling with USDC helped drive our upgrade of Circle, says Mizuho’s Dan Dolev

February 25, 2026

Mizuho news from around the globe

back-to-top-blue